Serum VEGF Predicts Clinical Improvement Induced by Cerebrolysin Plus Donepezil in Patients With Advanced Alzheimer's Disease.

RPEP-046322020RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Not classified
Evidence
Not graded
Sample
Not reported

What This Study Found

Key Numbers

How They Did This

Why This Research Matters

What This Study Doesn't Tell Us

Trust & Context

Original Title:
Serum VEGF Predicts Clinical Improvement Induced by Cerebrolysin Plus Donepezil in Patients With Advanced Alzheimer's Disease.
Published In:
The international journal of neuropsychopharmacology, 23(9), 581-586 (2020)
Database ID:
RPEP-04632

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Read More on RethinkPeptides

Related articles coming soon.

Cite This Study

RPEP-04632·https://rethinkpeptides.com/research/RPEP-04632

APA

Alvarez, X Anton; Alvarez, Irene; Martinez, Antia; Romero, Iria; Benito, Concha; Suarez, Irene; Mourente, Silvia; Fantini, Manuel; Figueroa, Jesús; Aleixandre, Manuel; Linares, Carlos; Muresanu, Dafin; Winter, Stefan; Moessler, Herbert. (2020). Serum VEGF Predicts Clinical Improvement Induced by Cerebrolysin Plus Donepezil in Patients With Advanced Alzheimer's Disease.. The international journal of neuropsychopharmacology, 23(9), 581-586. https://doi.org/10.1093/ijnp/pyaa046

MLA

Alvarez, X Anton, et al. "Serum VEGF Predicts Clinical Improvement Induced by Cerebrolysin Plus Donepezil in Patients With Advanced Alzheimer's Disease.." The international journal of neuropsychopharmacology, 2020. https://doi.org/10.1093/ijnp/pyaa046

RethinkPeptides

RethinkPeptides Research Database. "Serum VEGF Predicts Clinical Improvement Induced by Cerebrol..." RPEP-04632. Retrieved from https://rethinkpeptides.com/research/alvarez-2020-serum-vegf-predicts-clinical

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.